Unprecedented Results From the Phase 3 MajesTEC-3 Study Support Tecvayli Plus Darzalex Faspro as a Potential Standard of Care as Early as Second Line for Patients With Relapsed/refractory Multiple Myeloma
December 10, 2025
December 10, 2025
RARITAN, New Jersey, Dec. 10 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI(R) plus DARZALEX FASPRO(R) as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
TECVAYLI(R) and DARZALEX FASPRO(R) combination led to a statistically significant progression-free survival and overall survival advantag . . .
* * *
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI(R) plus DARZALEX FASPRO(R) as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
TECVAYLI(R) and DARZALEX FASPRO(R) combination led to a statistically significant progression-free survival and overall survival advantag . . .